Related Experiment Video
Updated: Apr 5, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
13.0K
ProGRP is a possible tumor marker for patients with Ewing sarcoma.
Ken Yamaguchi1, Hirohisa Katagiri, Mitsuru Takahashi
1Shizuoka Cancer Center Hospital.
Biomedical Research (Tokyo, Japan)
|August 25, 2015
Summary
Serum ProGRP levels may indicate Ewing sarcoma. Elevated ProGRP was found in 5/9 Ewing sarcoma patients, suggesting potential neuroendocrine differentiation and a specific tumor marker for this rare cancer.
Area of Science:
- Biochemistry
- Oncology
- Pathology
Background:
- Pro-gastrin-releasing peptide (ProGRP) is a known tumor marker for small-cell lung carcinoma.
- Ewing sarcoma is a rare bone and soft tissue malignancy with unclear differentiation markers.
Purpose of the Study:
- To investigate serum ProGRP levels in Ewing sarcoma patients.
- To explore the potential of ProGRP as a tumor marker for Ewing sarcoma.
- To assess neuroendocrine differentiation in Ewing sarcoma.
Main Methods:
- Serum ProGRP levels were measured in Ewing sarcoma patients.
- Immunohistochemical analysis of ProGRP-like immunoreactivity in tumor tissues.
- Comparison with ProGRP levels in other malignancies.
Main Results:
- Elevated serum ProGRP levels were observed in 5 out of 9 Ewing sarcoma patients.
- ProGRP-like immunoreactivity was detected in Ewing sarcoma tissues.
- Serum ProGRP levels were not elevated in other bone and soft tissue malignancies.
Conclusions:
- Serum ProGRP may serve as a specific tumor marker for Ewing sarcoma.
- The findings suggest that Ewing sarcoma may exhibit neuroendocrine differentiation.
- Further research is warranted to validate ProGRP as a diagnostic and prognostic marker for Ewing sarcoma.
